Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Urogen Pharma Ltd Ordinary Shares (URGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 623,013
  • Shares Outstanding, K 13,750
  • Annual Sales, $ 8,160 K
  • Annual Income, $ -20,000 K
  • 36-Month Beta 2.47
  • Price/Sales 76.12
  • Price/Cash Flow N/A
  • Price/Book 6.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -1.31
  • Number of Estimates 5
  • High Estimate -1.18
  • Low Estimate -1.46
  • Prior Year -0.74
  • Growth Rate Est. (year over year) -77.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.61 +11.43%
on 12/06/18
50.99 -11.26%
on 11/26/18
-1.42 (-3.04%)
since 11/09/18
3-Month
36.95 +22.46%
on 10/25/18
50.99 -11.26%
on 11/26/18
+0.10 (+0.22%)
since 09/11/18
52-Week
36.66 +23.43%
on 12/14/17
69.57 -34.96%
on 05/21/18
+7.54 (+19.99%)
since 12/11/17

Most Recent Stories

More News
UroGen Pharma Reports Third Quarter 2018 Financial Results and Completed UGN-101 OLYMPUS Trial Enrollment

--Breakthrough Therapy Designation (BTD) Previously Granted by the FDA for UGN-101 for the Treatment of LG UTUC

URGN : 45.25 (-0.13%)
UroGen Pharma to Present at November 2018 Investor Conferences

UroGen Pharma Ltd. (Nasdaq:URGN), today announced that management will present at two investor conferences in November 2018:

URGN : 45.25 (-0.13%)
UroGen Pharma to Report Third Quarter 2018 Financial Results on Monday, November 12, 2018

UroGen Pharma Ltd. (NASDAQ:URGN) today announced that it will report third quarter 2018 financial results on Monday, November 12, 2018, prior to the open of the market. The announcement will...

URGN : 45.25 (-0.13%)
FDA Grants Breakthrough Therapy Designation (BTD) for UroGen Pharma's UGN-101 for the Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC)

--On Track to Initiate Rolling Submission of UGN-101 New Drug Application (NDA) in Q4 2018

URGN : 45.25 (-0.13%)
UroGen Pharma to Present at the Ladenburg Thalmann 2018 Healthcare Conference

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced...

URGN : 45.25 (-0.13%)
Jones "Woody" Bryan Joins UroGen Pharma as Senior Vice President of Business Development

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company, today announced that Jones "Woody" Bryan, Ph.D. has been appointed as Senior Vice President of Business Development....

URGN : 45.25 (-0.13%)
UroGen Pharma Reports First Quarter 2018 Financial Results and Recent Corporate Developments

Interim Analysis of Pivotal Phase 3 OLYMPUS Trial of UGN-101 (MitoGel(TM)) for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma (LG UTUC) to be Presented at American Urological Association (AUA)...

URGN : 45.25 (-0.13%)
UroGen Pharma to Report First Quarter 2018 Financial Results on Tuesday, May 15, 2018

Conference Call and Webcast Scheduled for 8:30 AM ET

URGN : 45.25 (-0.13%)
Factors of Influence in 2018, Key Indicators and Opportunity within Dorman Products, Arch Capital Group, Acacia Communications, UROGEN PHARMA, CyrusOne, and TCP Capital -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Dorman Products, Inc. (NASDAQ:DORM),...

URGN : 45.25 (-0.13%)
ACIA : 41.47 (+1.67%)
TCPC : 14.40 (+1.48%)
DORM : 82.89 (+1.15%)
ACGL : 27.45 (-0.44%)
CONE : 58.82 (+1.94%)
Today's Research Reports on Stocks to Watch: UroGen Pharma and Novartis

NEW YORK, NY / ACCESSWIRE / April 4, 2018 / Shares of Novartis and UroGen both saw gains in Tuesday trading. UroGen saw its shares climb after announcing new data presentation from an interim analysis...

URGN : 45.25 (-0.13%)
NVS : 87.36 (+0.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade URGN with:

Business Summary

UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen...

See More

Key Turning Points

2nd Resistance Point 48.71
1st Resistance Point 47.01
Last Price 45.25
1st Support Level 42.55
2nd Support Level 39.78

See More

52-Week High 69.57
Fibonacci 61.8% 57.00
Fibonacci 50% 53.11
Fibonacci 38.2% 49.23
Last Price 45.25
52-Week Low 36.66

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar